Posted on 10/11/17
OnePath Medical Expands Services for MD, NY, and PA Patients Needing Medical Cannabis
OnePath Medical, a software provider used to connect doctors with patients needing medical cannabis, today announced that it has expanded its services to Maryland, New York, . . .
Posted on 10/10/17
Better Buy: Celgene Corporation vs. Bristol-Myers Squibb
By most metrics, Celgene Corporation (NASDAQ:CELG) is smaller than Bristol-Myers Squibb (NYSE:BMY). Celgene has fewer employees, lower revenue, and lower earnings than BMS does. In one . . .
Posted on 10/10/17
Pfizer: Improving Dividend Prospects
Image creditShares of Pfizer (PFE) are always known for the ample yield they pay - currently around 3.5% - but in terms of price appreciation, PFE . . .
Posted on 10/9/17
22nd Century Group Announces $54 Million Common Stock Only Registered Direct Offering
CLARENCE, N.Y.--(BUSINESS WIRE)--22nd Century Group, Inc. (NYSE American: XXII), a plant biotechnology company that is focused on tobacco harm reduction, announced today that it has entered . . .
Posted on 10/6/17
Why Regeneron Pharmaceuticals Dropped 11.3% in September
What happenedDespite sharing a series of positive news items with investors, shares of biotech-giant Regeneron Pharmaceuticals (NASDAQ:REGN) fell more than 11% in September, according to data . . .
Posted on 10/6/17
Q BioMed Announces Launch of PainFreeCancer.com Website
Q BioMed Inc., a New York-based biotechnology acceleration company, announced today the launch of www.PainFreeCancer.com. This website is designed to provide a resource for patients, doctors . . .
Posted on 10/6/17
Relmada Therapeutics Announces $6.9 Million Private Placement
Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, today announced a private placement of . . .
Posted on 10/6/17
MD Magazine and Contagion Partner with Fenway Health
CRANBURY, N.J.--(BUSINESS WIRE)--MD Magazine®, a leading online and print source of physician news, conference coverage, and peer-to-peer discussion, and Contagion®, an all-inclusive resource for infectious disease . . .
Posted on 10/4/17
Rare Disease Report and CURE Magazine Welcome the Fibrolamellar Cancer Foundation as a Strategic Alliance Partner
CRANBURY, N.J.--(BUSINESS WIRE)--Rare Disease Report® (RDR®) and CURE® magazine have joined forces with the Fibrolamellar Cancer Foundation (FCF) through the Strategic Alliance Partnership (SAP) program, announced . . .
Posted on 10/4/17
Akari Therapeutics: What's Next For This 'Busted IPO'?
Today we look at a small-cap concern I received a question on from a Biotech Forum member last week that I had not previously researched. It . . .
Posted on 10/4/17
Johnson & Johnson: Best of Breed in Healthcare
Johnson & Johnson (JNJ) is considered by many to be one of the best long-term stocks, due to its consistent high performance throughout many decades of . . .
Posted on 10/4/17
Is This How Drugmakers Will Kill Biosimilars?
Pfizer (NYSE:PFE) has filed a lawsuit accusing Johnson & Johnson (NYSE:JNJ) of strong-arming insurers into excluding its Remicade biosimilar, Inflectra, from their reimbursement lists. If drugmakers . . .
Posted on 10/4/17
Community Care Physicians Signs Agreement with Humana
ALBANY, N.Y.--(BUSINESS WIRE)--Community Care Physicians (CCP) and health and well-being company Humana Inc.(NYSE: HUM) have signed a new value-based agreement that provides in-network access for Humana . . .
Posted on 10/3/17
Pfizer: A Good Buy
I find Pfizer (PFE) a truly wonderful business. The reason for this is because the company is able to present its investors year after year with . . .
Posted on 10/3/17
More Proof Pfizer's Dividend Is The Only Reason To Own It
Photo creditPfizer (PFE) shares never seem to go anywhere despite the company's enormous R&D budget and equally impressive acquisitions. That's interesting but given the tremendous pace . . .
Posted on 10/3/17
Celgene Could Be A $200 Stock
Since its spin-off from Celanese in 1986, Celgene (CELG) has built an active pipeline of drugs that focus on treatments for cancer and inflammatory diseases. Additionally, . . .
Posted on 10/3/17
Best Buy: Johnson & Johnson, Pfizer, or Gilead Sciences?
Remember the old game show "Let's Make a Deal"? It was originally hosted by the recently deceased Monty Hall, and its current iteration is hosted by . . .
Posted on 10/3/17
Better Buy: Gilead Sciences, Inc. vs. Pfizer
The biopharmaceutical industry has been exceptionally kind to investors over the past six years because of the introduction of several new classes of drugs, greater insurance . . .
Posted on 10/3/17
Intra-Cellular Therapies Closes $150 Million Public Offering
NEW YORK, Oct. 02, 2017 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company, today announced the completion of its previously announced underwritten public offering . . .
Posted on 10/2/17
Pfizer Exposes the Sordid Underbelly of Drug Prices
Johnson & Johnson's (NYSE:JNJ) one of the largest drugmakers in the world, and according to a lawsuit Pfizer (NYSE:PFE) has filed, it's leveraging its size to . . .
Posted on 10/2/17
Best Buy: Johnson & Johnson, Pfizer, or Gilead Sciences?
Remember the old game show "Let's Make a Deal"? It was originally hosted by the recently deceased Monty Hall, and its current iteration is hosted by . . .
Posted on 10/2/17
Tina's Wish Celebrates its 10th Anniversary at the American Museum of Natural History
More than 700 Tina's Wish supporters came together during Ovarian Cancer Awareness Month to raise $1.6M for critical research initiatives at the Foundation's Annual Benefit Dinner . . .
Posted on 9/29/17
Kadmon Announces Closing of $80.4 Million Public Offerings
NEW YORK--(BUSINESS WIRE)--Kadmon Holdings, Inc. (NYSE:KDMN) today announced the closing of its previously announced public offerings for gross proceeds of approximately $80.4 million, which includes the . . .
Posted on 9/28/17
Johnson & Johnson Investors, Mark Your Calendars for October
After a nice jump in the first half of 2017, Johnson & Johnson (NYSE:JNJ) stock has largely tread water over the last few months. Wouldn't it . . .
Posted on 9/28/17
Intra-Cellular Therapies Prices $150 Million Public Offering of Common Stock
NEW YORK, Sept. 27, 2017 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company, today announced the pricing of its previously announced underwritten public offering . . .

